Concepedia

Philip Reigan

PR

Statistics

Publications

53

Citations

2.5K

H-Index

30

Active since

2002

Affiliations

University of Colorado Denver(Current)

University of Colorado Anschutz Medical Campus

University of Montana

University of Nottingham

University of Colorado Health

Philip Reigan is an author at University of Colorado Denver specializing in pharmacology, life sciences, and oncology.

ORCID

Publications per year

2002–2024

53

Publications

53

Formation of 17-Allylamino-Demethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:Quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition

Wenchang Guo, Philip Reigan, David Siegel et al. · Cancer Research · 2005 · 176 citations

, , +15

Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics <i>In Vitro</i> and <i>In Vivo</i> , Independent of p53 Functionality

Annemie A. Van Linden, Dmitry Baturin, James B. Ford et al. · Molecular Cancer Therapeutics · 2013 · 128 citations · Full text

, , +15

The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation

Maria L. Amaya, Anagha Inguva Sheth, Shanshan Pei et al. · Blood · 2021 · 128 citations · Full text

, , +15

4-Hydroxynonenal Inhibits SIRT3 via Thiol-Specific Modification

Kristofer S. Fritz, James J. Galligan, Rebecca L. Smathers et al. · Chemical Research in Toxicology · 2011 · 125 citations

, , +17

Acrolein Inhibits Cytokine Gene Expression by Alkylating Cysteine and Arginine Residues in the NF-κB1 DNA Binding Domain

Cherie Lambert, Jimei Li, Karen R. Jonscher et al. · Journal of Biological Chemistry · 2007 · 115 citations · Full text

, , +13

1–5 of 53